Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

Cancer immunology research - 1 Jun 2014

Tjin Esther P M, Krebbers Gabrielle, Meijlink Kimberley J, van de Kasteele Willeke, Rosenberg Efraim H, Sanders Joyce, Nederlof Petra M, van de Wiel Bart A, Haanen John B A G, Melief Cornelis J M, Vyth-Dreese Florry A, Luiten Rosalie M

Abstract excerpt

In this study, we investigated a large series of immune (escape) markers, relevant to T-cell function, as potential biomarkers for clinical outcome following immunotherapy. We retrospectively studied the expression of immune (escape) markers in metastatic melanoma tissues of 27 patients before au...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Granulocyte-Macrophage Colony-Stimulating Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Immunotherapy

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Tumor Escape

Source

Identifiers

PMID: 24894091
DOI: 10.1158/2326-6066.CIR-13-0097

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24894091-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.PMID 24894091Read ↗

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.Semantic proximity Read ↗

Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.Semantic proximity Read ↗

Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.Semantic proximity Read ↗

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.Semantic proximity Read ↗

Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.Semantic proximity Read ↗

Lymphocyte subpopulations in melanoma patients treated with dendritic cell vaccines.Semantic proximity Read ↗

Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.Semantic proximity Read ↗

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.Semantic proximity Read ↗

Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.Semantic proximity Read ↗

Tumour immunology, vaccination and escape strategies.Semantic proximity Read ↗

Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.Semantic proximity Read ↗

Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.